Answers are grounded in this paper and cite their sources.
Retrospective analysis examines mobilization outcomes post-CD38 induction in multiple myeloma, highlighting plerixafor's role.
Background High‐dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of care for fit patients with newly diagnosed multiple myeloma (MM). The increasing use of CD38 antibody‐based quadruplet induction regimens such as daratumumab‐VTd (Dara‐VTd) has raised concerns regarding impaired stem cell mobilization. Study Design and Methods We conducted a retrospective single‐center analysis comparing steady‐state stem cell mobilization after Dara‐VTd versus bortezomib–cyclophosphamide–dexamethasone (VCd) induction. Mobilization kinetics, plerixafor use, and CD34 + collection outcomes were evaluated. CD34 + counts prior to first apheresis were adjusted for plerixafor use (adjCD34 + ). Multivariate logistic regression was performed to identify predictors of mobilization success. Results Among 153 patients, 85 received Dara‐VTd and 68 received VCd. Despite significantly deeper responses after Dara‐VTd (≥VGPR 81% vs. 42%; p < .01), these patients showed lower adjCD34 + counts prior to first apheresis (16 vs. 50/μL; p < .01) and required plerixafor more frequently (64% vs. 15%; p < .01). Nevertheless, cumulative CD34 + yields were comparable between Dara‐VTd and VCd (6.4 vs. 6.0 × 10 6 CD34 + cells/kg; p = .15), and target yields were achieved in the majority of patients proceeding to apheresis (90% vs. 94%). Dara‐VTd induction, prior radiation, and high tumor burden were identified as independent negative predictors of mobilization success. Discussion Although Dara‐VTd induction is associated with impaired mobilization kinetics, successful steady‐state mobilization remains feasible. On‐demand plerixafor use overcomes mobilization deficits, supporting this approach in patients receiving CD38‐based quadruplet induction therapy. Furthermore, follow‐up analysis of stem cell graft utilization demonstrates a high proportion of collected but unused stem cell grafts in both cohorts.
No takes yet. Share an insight, caveat, or question.
Röhnert et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: